Vaxcyte, Inc. PCVX
We take great care to ensure that the data presented and summarized in this overview for Vaxcyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PCVX
View all-
Vanguard Group Inc Valley Forge, PA11.4MShares$991 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$946 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$861 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$753 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$424 Million0.12% of portfolio
-
Wellington Management Group LLP Boston, MA4.51MShares$391 Million0.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.47MShares$387 Million0.06% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.05MShares$351 Million0.28% of portfolio
-
State Street Corp Boston, MA3.41MShares$295 Million0.02% of portfolio
-
Franklin Resources Inc San Mateo, CA2.79MShares$241 Million0.1% of portfolio
Latest Institutional Activity in PCVX
Top Purchases
Top Sells
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Insider Transactions at PCVX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2025
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Open market or private sale
|
Direct |
8,000
-2.31%
|
$696,000
$87.01 P/Share
|
|
Jan 21
2025
|
Andrew Guggenhime PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+6.38%
|
$40,000
$5.35 P/Share
|
|
Jan 15
2025
|
Teri Loxam Director |
SELL
Open market or private sale
|
Direct |
6,250
-7.46%
|
$525,000
$84.54 P/Share
|
|
Jan 15
2025
|
Teri Loxam Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+31.77%
|
$137,500
$22.7 P/Share
|
|
Jan 06
2025
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
5,000
-5.15%
|
$425,000
$85.7 P/Share
|
|
Jan 06
2025
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+13.08%
|
$105,000
$21.41 P/Share
|
|
Jan 02
2025
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-1.26%
|
$664,000
$83.67 P/Share
|
|
Jan 02
2025
|
Jim Wassil CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+3.61%
|
$16,000
$2.42 P/Share
|
|
Dec 18
2024
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Open market or private sale
|
Direct |
8,000
-1.74%
|
$704,000
$88.88 P/Share
|
|
Dec 18
2024
|
Andrew Guggenhime PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+6.38%
|
$40,000
$5.35 P/Share
|
|
Dec 16
2024
|
Elvia Cowan SVP, FINANCE |
BUY
Exercise of conversion of derivative security
|
Direct |
7,716
+28.57%
|
$192,900
$25.92 P/Share
|
|
Dec 09
2024
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Indirect |
2,366
-0.43%
|
$217,672
$92.7 P/Share
|
|
Dec 09
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Payment of exercise price or tax liability
|
Direct |
475
-1.66%
|
$43,700
$92.06 P/Share
|
|
Dec 06
2024
|
Carlos V Paya Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,500
+30.77%
|
-
|
|
Dec 06
2024
|
Carlos V Paya Director |
SELL
Bona fide gift
|
Direct |
2,500
-61.73%
|
-
|
|
Dec 05
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
5,000
-5.15%
|
$455,000
$91.66 P/Share
|
|
Dec 05
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.92%
|
$105,000
$21.41 P/Share
|
|
Dec 05
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Bona fide gift
|
Direct |
110
-0.38%
|
-
|
|
Dec 02
2024
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
15,000
-1.08%
|
$1,395,000
$93.06 P/Share
|
|
Dec 02
2024
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-1.26%
|
$744,000
$93.06 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 118K shares |
|---|---|
| Exercise of conversion of derivative security | 654K shares |
| Payment of exercise price or tax liability | 46.1K shares |
|---|---|
| Bona fide gift | 3.32K shares |
| Open market or private sale | 588K shares |